Symbols

SPPI(Delisted)

Spectrum Pharmaceuticals·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SPPI

Spectrum Pharmaceuticals, Inc.

A biopharmaceutical company focused on novel and targeted oncology

Industry

Established Date

Listing Date

09/27/1996

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sppirx.com

Security Type

Common stock

Office address

11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052

Business

Introduction

Spectrum Pharmaceuticals, Inc., is a biotechnology company with a full range of commercial and drug development operations focused on oncology. The Company was incorporated as a Delaware corporation in Colorado in December 1987, initially as Amelix Financing Corporation, in August 1996 as NeoTherapeutic Corporation, in June 1997 as a Delaware Corporation, and in December 2002 as Spectrum Pharma Corporation. This company is a diversified pipeline whose strategy includes acquisition, development and commercialization of late-stage clinical and commercialization. The company currently sells three oncology drugs: FUSILEV, FOLOTYN, ZEVALIN and two drugs: apaziquone and belinostat, as well as a diversified pipeline of new drug candidates in late-stage development. The company integrates its internal scientific research team, including its formulation development, clinical development, medical research, legal affairs, biostatistics and data management, and builds the marketing business infrastructure for its desired products. The company unites collaborating experts from around the world to help real-time their strategy. In 2012, Apaziquone initiated research with strategic partner Allergan in the third phase of a large clinical trial for non-muscle invasive bladder cancer, while maintaining cooperation with Nippon Kayaku and Handok Pharmaceuticals. Spectrum Pharma and TopoTarget are strategically partnering in the second phase of a clinical trial to study multiple adaptive symptoms, namely relapsed or refractory T-lymphocyte carcinoma.

Company Financials

EPS

SPPI has released its 2023 Q1 earnings. EPS was reported at -0.02, versus the expected -0.06, beating expectations. The chart below visualizes how SPPI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SPPI has released its 2023 Q1 earnings report, with revenue of 15.62M, reflecting a YoY change of NaN%, and net profit of -5.01M, showing a YoY change of 67.58%. The Sankey diagram below clearly presents SPPI's revenue sources and cost distribution.